Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: "VIVUS, Inc." (VVUS) Report Updated: Oct 05, 2015 | Print This Page

Get more stock ratings by Louis Navellier

"VIVUS, Inc." (VVUS)

Rating: Sell Volatility: Aggressive
Total Grade: D Industry: Pharmaceuticals
Competitors: AXN, PAHC, HSKA, SCMP

Stock Analysis

Rating: Monthly View

October November December January February March April May June July August September

Rating: Weekly View

This Week: D down upgrade
Last Week: F same no change
Two Weeks Ago: F up downgrade
service keys

"VIVUS, Inc."© quotemedia

Company Profile

VIVUS, Inc., a biopharmaceutical company, is developing therapies to address obesity, sleep apnea, diabetes, and male sexual health. Its lead investigational product, Qnexa, has completed Phase 3 clinical trials for the treatment of obesity. Qnexa is also in Phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. The company’s investigational drug candidate also comprises avanafil, a Phase 3 clinical studies completed product to treat erectile dysfunction. VIVUS, Inc. has a licensing agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Avanafil. The company was founded in 1991 and is headquartered in Mountain View, California.

Recent News: "VIVUS, Inc."